281-296-7300

  • Awards
  • Careers
logo
  • About
    • About VGXI
    • Leadership
    • VGXI Mission
    • Awards
    • Careers
  • Services
    • Manufacturing Services
    • cGMP Plasmid
    • HD Plasmid
    • Pre-Clinical Plasmid
    • Additional Services
  • VGXI Process
    • VGXI Manufacturing Process
    • Analytical Testing
    • Quality Systems
  • Resource Center
    • News
    • Events
    • FAQs
    • Whitepapers
    • Posters & Presentations
  • Contact Us
  • Awards
  • Careers

Year: 2013

Roche and Inovio Pharmaceuticals partner on Inovio’s prostate cancer and hepatitis B immunotherapy products

October 24, 2013

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal… Read More »

Filed Under: News

2013 BIO International Convention Exhibition

October 24, 2013

VGXI will be exhibiting at the 2013 BIO International Convention being held on April 22-25 in Chicago, Illinois. We will be located in the Contract Services Zone at Booth 1873. Make sure you stop by and check out what we have to offer. We can’t wait to see you there!  

Filed Under: News

[BLOG] Dengue Fever 101

September 6, 2013

Since it became a global issue during World War II, researchers and scientists have been struggling to develop a vaccine for Dengue fever.  To date, there has been no success in eradicating this disease.  Before we get to the specifics of the challenges this disease presents, let’s cover the symptoms related to this tropical disease…. Read More »

Filed Under: Blog

DNA Vaccine for Malaria Demonstrates Ability to Kill Infected Cells

August 23, 2013

A new potential vaccine for malaria is gaining media attention after successful pre-clinical trials in small animals and non-human primates.  Until now, the most effective malaria vaccine in human clinical trials has been GSK’s RTS,S vaccine.  Their vaccine demonstrated a 50% efficacy in children between the ages of 5 and 17 months and only a 30%… Read More »

Filed Under: Blog

Brazilian DNA Vaccine for AIDS to be Tested in Rhesus Monkeys

August 16, 2013

In development since 2001, the HIVBr18 DNA vaccine developed at the Medical School at the University of Sao Paulo (USP) in Brazil may prevent transmission of human immunodeficiency virus (HIV) and development of acquired immune deficiency syndrome (AIDS). The DNA Vaccine encodes 18 conserved multiple HLA-DR-binding HIV-1 CD4 epitopes capable of eliciting broad CD4(+) T… Read More »

Filed Under: Blog

Combination Cell & Gene Therapy for Brain Metastases of Breast Cancer

August 9, 2013

New research out of the UCLA Jonsson Comprehensive Cancer Center (JCCC) led by Carol Kruse, professor of neurosurgery, combined two therapies currently undergoing individual clinical trials to determine if the two used in tandem could demonstrate a greater efficacy and reduction of tumor size than either therapy alone. Dr. Kruse’s combination therapy includes both a… Read More »

Filed Under: Blog

VGXI Will Exhibit and Present Poster at ASGCT 2013

May 3, 2013

Filed Under: News

What Makes VGXI the Best Contract Manufacturing Organization?

May 3, 2013

VGXI was awarded the Vaccine Industry Excellence (ViE) Award for Best Contract Manufacturing Organization at the 6th Annual ViE Awards Ceremony held at the World Vaccine Congress on April 17th, 2013 in Washington, D.C. To read the full Press Release – click here. The following five categories illustrate what makes VGXI the Best Contract Manufacturing Organization… Read More »

Filed Under: Blog

VGXI Wins ViE Award for Best Contract Manufacturing Organization

April 19, 2013

VGXI announced today that it won the award for Best CMO at the 6th Annual ViE Awards Ceremony held at the 2013 World Vaccine Congress in Washington, D.C.. FOR IMMEDIATE RELEASE: The Woodlands, TX – April 19, 2013 – VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, is proud to announce… Read More »

Filed Under: News

Cell Line Optimization for DNA Vaccine Production

March 29, 2013

“Therapeutic plasmid DNA vector” is promising technology for the future of gene therapy. Though still in the clinical trial stage, DNA vaccines have great potential of being successful as effective vaccination technology with negligible side effects. One of the most important considerations in designing a successful DNA vaccine production process is the selection of an… Read More »

Filed Under: Blog

BIO International 2013

March 26, 2013

VGXI will exhibit at the 2013 BIO International Convention in Chicago, IL on April 22-25. We will be located at Booth 1873 in the Contract Services Zone.

Filed Under: News

2013 BIO International Convention Exhibition

March 26, 2013

VGXI will be exhibiting at the 2013 BIO International Convention being held on April 22-25 in Chicago, Illinois. We will be located in the Contract Services Zone at Booth 1873. Make sure you stop by and check out what we have to offer. We can’t wait to see you there!  

Filed Under: News

  • 1
  • 2
  • »

Archives

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • About
  • Services
  • VGXI Process
  • Contact Us
  • Careers
  • Awards
  • Resource Center
logo white

281-296-7300
2700 Research Forest Drive, Suite 180
The Woodlands, Texas 77381, USA

Teko Font
Please enter your name.
Please enter a valid email address.
Sign Up

Thanks for subscribing! Please check your email for further instructions.

Something went wrong. Please check your entries and try again.

© 2021 VGXI, Inc. All Rights Reserved.Terms | Privacy Policy